Winson Tang has seen his share of patients as a physician, but since completing his post-doctoral training at The Scripps Research Institute, Winson Tang has worked in positions of increasing responsibility at a number of biotechnology companies including Amgen, Tularik, Isis, and Sangamo BioSciences. Winson Tang has expertise in multiple technology platforms including proteins, small molecules, anti-sense oligonucleotides, and gene and cell therapy. Winson Tang has successfully developed multiple therapies that have been approved for commercialization in in both the United States and European Union.
We鈥檝e updated our privacy policy so that we are compliant with changing global privacy regulations and to provide you with insight into the limited ways in which we use your data.
You can read the details below. By accepting, you agree to the updated privacy policy.
